Finch Therapeutics Group, Inc. (FNCH)

Market Cap	45.99M
Revenue (ttm)	1.66M
Net Income (ttm)	-106.69M
Shares Out	47.73M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,395
Open	1
Previous Close	0.96
Day's Range	0.9 - 1
52-Week Range	0.83 - 14.87
Beta	n/a
Analysts	Buy
Price Target	13.52 (+1,322.9%)
Earnings Date	Nov 9, 2022

About FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism sp...

• Industry: Biotechnology
• IPO Date: Mar 19, 2021
• Employees: 189
• Stock Exchange: NASDAQ
• Ticker Symbol: FNCH

Financial Performance

In 2021, FNCH's revenue was $18.53 million, an increase of 140.08% compared to the previous year's $7.72 million. Losses were -$58.16 million, 47.8% more than in 2020.

Analyst Forecast

According to 9 analysts, the average rating for FNCH stock is "Buy." The 12-month stock price forecast is 13.52, which is an increase of 1,322.86% from the latest price.

Price Target

$13.52

(1,322.86% upside)

Analyst Consensus: Buy